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Impact of Percoll purification 
on isolation of primary human 
hepatocytes
R. Horner  1, J. G. M. V. Gassner1, M. Kluge1, p. Tang1, s. Lippert1, K. H. Hillebrandt  1, 
s. Moosburner  1, A. Reutzel-selke1, J. Pratschke1, I. M. sauer  1 & N. Raschzok1,2
Research and therapeutic applications create a high demand for primary human hepatocytes. The 
limiting factor for their utilization is the availability of metabolically active hepatocytes in large 
quantities. Centrifugation through Percoll, which is commonly performed during hepatocyte isolation, 
has so far not been systematically evaluated in the scientific literature. 27 hepatocyte isolations were 
performed using a two-step perfusion technique on tissue obtained from partial liver resections. Cells 
were seeded with or without having undergone the centrifugation step through 25% Percoll. Cell yield, 
function, purity, viability and rate of bacterial contamination were assessed over a period of 6 days. 
Viable yield without Percoll purification was 42.4 × 106 (seM ± 4.6 × 106) cells/g tissue. An average of 
59% of cells were recovered after Percoll treatment. There were neither significant differences in the 
functional performance of cells, nor regarding presence of non-parenchymal liver cells. In five cases 
with initial viability of <80%, viability was significantly increased by Percoll purification (71.6 to 87.7%, 
p = 0.03). Considering our data and the massive cell loss due to Percoll purification, we suggest that 
this step can be omitted if the initial viability is high, whereas low viabilities can be improved by Percoll 
centrifugation.
Primary human hepatocytes serve as the gold-standard model for in vitro testing of drugs that are metabolized 
in the liver1,2. In order to address the 3R-principle3, animal testing could be reduced with hepatocytes available 
on a grand scale. With highly metabolically active in vitro 3D-cultures of primary human hepatocytes, phar-
macokinetic processes of drug metabolism can be investigated without the need for using a xenogenous animal 
model4,5. Primary human hepatocytes can be used to study the pathogenesis of human liver diseases more thor-
oughly, especially in regard to the increasing number of patients suffering from non-alcoholic fatty liver disease6. 
Moreover, in face of the growing organ scarcity for liver transplantation, hepatocytes can help to provide bridging 
strategies until a suitable donor organ is available, e.g. by hepatocyte transplantation7–9, or be used for bioengi-
neering of neo-organs10,11. The wide application of primary human hepatocytes is, however, limited due to the 
lack of a safe, constant source of high-quality human liver cells.
Collagenase perfusion protocols have been an established procedure since the 1980s for isolation of primary 
human hepatocytes12. The best available and most commonly used source for human liver cells is tissue obtained 
from partial liver resection for therapeutic purposes, for example after removing a tumor (Fig. 1). After cannula-
tion, perfusion and enzymatic digestion of the tissue specimen, the resulting cell suspension contains liver cells 
that can be cultured for subsequent use. Optionally, hepatocyte suspensions are purified through density separa-
tion with Percoll, which is a low-density fluid containing colloidal silica particles coated with polyvinylpyrroli-
done13,14. This additional purification step is included to the isolation protocol in almost 50% of published studies 
on primary human hepatocytes in the literature reviewed for this study (see supplementary data). Percoll purifi-
cation can be used for splitting up different liver cell populations, for example Kupffer cells, stellate cells, hepatic 
progenitor cells, oval cells or liver sinusoidal endothelial cells by centrifuging the cell suspension through differ-
ently concentrated layers of Percoll15–18. Moreover, several publications19–21 report a Percoll purification step in 
their protocol to recover liver cells after cryopreservation. Nonetheless, density purification is also commonly 
1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu 
Berlin, and Berlin institute of Health, Department of Surgery, experimental Surgery, campus charité Mitte | campus 
Virchow-Klinikum, Berlin, Germany. 2BiH charité clinician Scientist Program, Berlin institute of Health (BiH), Berlin, 
Germany. Correspondence and requests for materials should be addressed to N.R. (email: nathanael.raschzok@
charite.de)
Received: 22 August 2018
Accepted: 12 April 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:6542  | https://doi.org/10.1038/s41598-019-43042-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
performed to purify parenchymal human hepatocytes themselves22–26, adding about 45 minutes to the 3 hours 
isolation procedure. Systemic evaluation of this cell- and time-consuming step in hepatocyte isolation is not cur-
rently available in the literature, specifically not for human primary liver cells.
With respect to the fact that the wider use of primary human hepatocytes is mainly limited by the lack of 
sufficient amount of hepatocytes11,27, it is crucial to know whether or not the Percoll purification step is necessary 
at all during hepatocyte isolation. The aim of this work is to investigate whether purification of primary human 
hepatocytes with density separation by Percoll has a beneficial effect on the performance of isolated human hepat-
ocytes; e. g. yield, viability, plating efficiency, metabolic function, purity, bacterial contamination levels28 and 
purity of cell cultures.
Methods
Study design and tissue retrieval. From October 2015 to July 2016, a total of 27 hepatocyte isolations 
were performed at the Department of Surgery, Campus Charité Mitte | Campus Virchow-Klinikum of the Charité 
– Universitätsmedizin Berlin (Germany). Liver tissue specimens were retrieved from patients undergoing partial 
hepatectomies. Informed consent was obtained from all tissue donors, and all institutional and ethical guidelines 
were followed (approval of local ethics committee “Ethikkommission der Charité – Universitätsmedizin Berlin”: 
EA2/137/09). Patients with infectious diseases such as viral hepatitis, multi-resistant bacteria, or echinococcosis 
were excluded from the study. All donor-related information was collected from the patient’s hospital records.
Liver tissue was examined for macroscopically tumor-free areas immediately after resection in the operating 
room. Tissue specimens used for hepatocyte isolation were cut with a scalpel with only one dissection surface, 
the rest of the liver specimen being covered by Glisson’s capsule. Mass of these specimens was 18.21 g on aver-
age (SEM ± 2.64 g). Tissue specimens were stored in a container filled with 4 °C cold Williams E-medium and 
transferred to the laboratory. All steps were performed under sterile conditions and the isolation protocol began 
within 30 minutes after retrieval of the specimen (=cold ischemic time). To prevent interpersonal variability, all 
hepatocyte isolations were carried out by a single person (RH).
Hepatocyte isolation and culturing. Hepatocytes were isolated using an established two-step-perfusion 
protocol with Collagenase P29. For this technique, sectioned major vessels were cannulated with 3–5 cannu-
las (custum-made stainless-stell irrigation cannulas) that where connected to thin plastic tubes, merged in a 
larger tube, and then connected to a roller pump for perfusion. Cannulas and major leakages were sealed with a 
histoacryl-tissue-glue (3 M, St. Paul, MN, USA). First, the tissue was rinsed with pre-warmed (37 °C) perfusion 
solution (containing 1.42 M NaCl, 67 mM KCl, and 100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
[all chemicals from Carl Roth GmbH, Karlsruhe, Germany]) supplemented with ethylene glycol tetraacetic acid 
(EGTA, Serva, Heidelberg, Germany) which is a chelator for Calcium ions that facilitates flushing the blood out 
of the specimen, hinder blood from clotting as well as disrupting the desmosomes between cells. This step was 
performed for 11.06 minutes (SEM ± 0.47) on average. Secondly, the liver specimen was perfused with recirculat-
ing perfusion solution containing 1 mg collagenase P/mL (Roche Diagnostics GmbH, Mannheim, Germany) at 
37 °C. Digestion was stopped when the tissue was visually and tactically deemed digested with a mean digestion 
time of 8.07 minutes (SEM ± 0.24). Afterwards, the specimen was transferred into a petri dish containing perfu-
sion solution without EGTA but supplemented with 4% human albumin to stop the enzymatic digestion. After 
removal of the cannulas, tissue was disrupted mechanically by shaking and using tweezers to disrupt cells from 
the remaining scaffold structures.
The resulting cell suspension was then centrifuged (5 minutes, 50 g, 4 °C) to eliminate cell debris. After resus-
pending in culture medium (phenol red free Williams E with supplements: 1 µM Insulin [Lilly, Indianapolis], 
1 µM Fortecortin [Merck Serono GmbH, Darmstadt, Germany], 1 mM sodium pyruvate, 10 mM HEPES-Buffer 
and 10% fetal calf serum [all from Biochrom]), cells were counted, and viability was assessed using the trypan 
Figure 1. Tissue retrieval and study design. Abbreviations: PHH: Primary human hepatocytes, NPC: non-
parenchymal cells, EGTA: ethylene glycol tetraacetic acid.
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blue exclusion test. A predetermined part of this “crude” suspension, i.e. without having undergone the Percoll 
purification step, was then seeded at a density of 1041 cells/mm² (1 million cells/well of a 6-well-plate) onto 
collagen-coated culture plates (Biochrom GmbH, Berlin, Germany) for cultivation.
Remaining cell suspension underwent the Percoll density separation by centrifugation through a Percoll 
layer (25% Percoll [Biochrom GmbH, Berlin, Germany] in phosphate buffered saline, 1.037 g/ml, 300mosm) 
for 20 minutes at 1474 g (4 °C). Therefore, 5 mL of cell suspension was gently mounted over a cushion of 15 mL 
Percoll-suspension. After careful aspiration of the supernatant, cell pellets were re-suspended with ice-cold PBS 
and centrifuged (5 minutes, 50 g, 4 °C) to wash out Percoll particles. After resuspension in medium, cells were 
counted and seeded as described above (Fig. 1). The cells were washed with pre-warmed PBS 4 hours after seed-
ing to discard non-attaching cells. Liver cells were cultured in modified Williams E (see above, additional 100 U/
mL/100 µg penicillin/streptomycin [Biochrom GmbH, Berlin, Germany]) for 6 days at 37 °C, 21% O2, 5% CO2. 
Medium was changed every 24 hours during the cultivation period.
Measurement of cell culture parameters. To measure the aspartate aminotransferase (AST) activity, 
albumin production and urea content, the supernatant of 3 pooled wells was centrifuged (3000 g, 5 min, 4 °C) 
Parameter








p-ValuePercoll− Percoll+ Percoll− Percoll+ Percoll− Percoll+ Percoll− Percoll+
Urea (mg/dL) 12.74 ± 2.30 9.84 ± 1.03 0.0532 11.71 ± 1.89 9.61 ± 1.12 0.2722 9.83 ± 1.70 8.10 ± 0.83 0.3205 8.18 ± 0.81 7.63 ± 0.69 0.1111
Albumin (ng/mL) 1843.41 ± 529.30 1884.05 ± 466.00 0.8906 1817.28 ± 542.40 1625.02 ± 215.40 0.3683 897.36 ± 259.00 1474.38 ± 363.20 0.0004 716.08 ± 192.82 835.26 ± 191.45 0.3225
AST (U/L) 82.37 ± 18.67 52.71 ± 6.13 0.0090 36.56 ± 4.27 31.56 ± 3.83 0.0516 29.38 ± 6.67 22.14 ± 1.96 0.3525 29.98 ± 2.96 33.77 ± 3.62 0.0425
Table 1. In vitro hepatocyte function.
Figure 2. Yield and viability of the overall group. Comparison of liver cell isolation without vs. with Percoll 
purification, n = 27. Viability: Box plots show the 25th and 75th percentile and median value, whiskers display 
smallest and largest value. Yield: Columns display mean value, whiskers indicate SEM.
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Figure 3. Functional parameters of the overall group. Comparison of hepatocytes isolated without or with 
Percoll purification (n = 27). Plating efficiency: Box plots show the 25th and 75th percentile and median value, 
whiskers display smallest and largest value. Urea, AST, Albumin: Columns display mean value, whiskers 
indicate SEM. Abbreviations: AST: aspartate aminotransferase, SEM: standard error of mean.
Figure 4. q-rt-PCR. q-rt-PCR displayed by the 2−ΔΔCT-Method: values > 1 indicate higher expression of the 
gene in preparations without Percoll purification, while values < 1 mean higher expression in the Percoll-
purified samples. Box plots show the 25th and 75th percentile and median value, whiskers display smallest and 
largest value.
5Scientific RepoRts |          (2019) 9:6542  | https://doi.org/10.1038/s41598-019-43042-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
after culturing overnight and after 2, 4, and 6 days in culture. Measurement of AST and Urea was conducted 
by Labor Berlin – Charité Vivantes GmbH (Berlin, Germany) within 12 hours of cold storage of the samples 
using an enzymatic assay (Roche Hitachi cobas c 6000 system, Roche Diagnostics GmbH, Mannheim, Germany). 
Albumin production was assessed using the human albumin ELISA kit (Bethyl Laboratories, Montgomery, TX, 
USA) after supernatant sample storage at −80 °C. ELISA samples were measured as duplets and according to the 
manufacturer’s instructions. All data was set in relation to the protein-content of the respective wells at the end 
of culture (day 6). For protein content measurement, the cells from these wells were washed, scratched off the 
culture plates, pooled, suspended with RIPA-Buffer and stored at −80 °C until being measured. Finally, photo-
metric analysis using BCA-Reagent (Pierce, Thermo Fisher Scientific, MA, USA) according to the manufacturers’ 
instructions was performed with all samples measured in triplets. Plating efficiency was evaluated using a pro-
tocol as described elsewhere29: The cells were washed 24 hours after seeding them. Subsequently, the adherent 
protein was set in relation to the sum of the adherent protein and the total protein contained in the supernatants 
at that time-point.
Purity assay. Purity of the composition of the cell culture was assessed using real-time quantitative 
(q-rt)-PCR. RNA samples were collected from 12 isolations 4 h after seeding, on days 2, 4 and 6 of culture. After 
Figure 5. Immunofluorescence. Fluorescence microscopy of hepatocyte cultures without (A,C,E,G) of after 
(B,D,F,H) purification with Percoll. Time points: 24 hours after seeding (A,B,E,F) and on Day 6 (C,D,G,H). 
A-D display KRT18-staining (hepatocytes), E-H display Pecam1-staining (endothelial cells). Scale bar: 50 µm.
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washing with PBS, cells were pooled in RNAase-free Eppendorfer containers containing TRIzol® (Thermo Fisher 
Scientific, Waltham, MA, USA) and immediately shock frozen in liquid nitrogen. Isolation and RNA measure-
ments were performed according to the established protocols using a NanoDrop 2000c UV-Vis spectrophotom-
eter (Thermo Fisher Scientific, Waltham, MA, USA) for calculating RNA-concentration. The RevertAid First 
Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA) in a PTC-100® Thermal Cycler 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used for generating cDNA. Gene expression was assessed 
using a StepOne™ RT-PCR cycler (ThermoFisher Scientific, Venlo, Netherlands). The following established 
DNA-primers were used (Abcam, Cambridge, United Kingdom): KRT18 (hepatocytes, Vim (fibroblasts), GGT1 
(cholangiocytes), Pecam1 (sinusoidal endothelial cells) and CD68 (Kupffer cells). B2M was chosen as an endog-
enous control because it had been established to be unregulated in random samples before. Results are shown 
using the R = 2(−ΔΔCT) method as described elsewhere30.
Additionally, these markers were stained in an immunofluorescence assay on culture plates that were fixed 
24 h after seeding and at the end of the culture period. Cells were fixated with 4% formaldehyde and stored in 
methanol until staining.
Microbiological testing. In 16 isolations, cell suspension underwent microbiological testing directly before 
seeding. A fraction of 5 ml of the cell suspension were transferred into aerobic and anaerobic blood culture bottles 
Figure 6. Phase contrast images. Phase contrast microscopy of hepatocyte cultures without (A,C) of after (B,D) 
purification with Percoll. Time points: 24 hours after seeding (A,B) and on Day 6 (C,D). Scale bar: 50 µm.
Parameter






p-ValuePercoll− Percoll+ Percoll− Percoll+ Percoll− Percoll+
Plating efficiency (%) 27.19 ± 2.19 31.77 ± 2.99 0.0455 29.92 ± 1.87 34.33 ± 3.05 0.0783 11.735 ± 2.47 16.46 ± 3.48 0.4312
Viablility (%) 84.47 ± 1.60 88.18 ± 1.13 0.0299 87.39 ± 0.91 88.29 ± 1.27 0.3209 71.63 ± 4.44 87.70 ± 2.79 0.0625
Percoll survival (%) 59.03 ± 3.90 59.63 ± 4.10 56.38 ± 12.02
Relative yield in millions per gram liver tissue 42.40 ± 4.60 26.60 ± 4.00 <0.0001 46.15 ± 4.95 29.18 ± 4.40 <0.0001 25.90 ± 9.72 15.30 ± 8.66 0.0299
Total protein on culture plate on day 6 596.20 ± 66.79 662.70 ± 61.98 0.0102 643.76 ± 73.55 716.71 ± 66.50 0.0156 334.38 ± 79.79 365.58 ± 55.33 0.6250
Table 2. Subgroup analysis of isolation outcome parameters.
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before and after Percoll purification. During 5 days of incubation, bacterial growth was examined by the Labor 
Berlin – Charité Vivantes GmbH (Berlin, Germany).
Statistical analysis. Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad Software, Inc., 
La Jolla, CA, USA). After testing Gaussian distribution with the Shapiro-Wilk-test, either a paired t-test or a 
Wilcoxon matched-pairs-signed-rank-test was done to analyze paired quantitative parameters. A p-value less 
than 0.05 was considered significant. All data is expressed as the mean ± standard error of the mean (SEM).
Results
Isolation outcome. Isolation outcome parameters are expressed in relation to the respective mass of the 
liver specimen. The isolation outcome yielded 42.4 (±4.6) × 106 isolated cells per gram liver tissue on crude cells 
without Percoll purification and 26.6 (±4.0) × 106 cells per gram liver tissue after Percoll purification (Fig. 2). This 
resulted in an average Percoll survival rate of 59.03% (±3.9). Viability was significantly increased (p = 0.0299) 
from 84.47% (±1.60) to 88.18% (±1.13) by Percoll purification.
Functional parameters. Comparing functional parameters of isolated cells, plating efficiency was signifi-
cantly (p = 0.046) increased in Percoll-purified cells (from 27.19 ± 2.19% to 31.77 ± 2.98%). Albumin, urea and 
AST levels are shown relative to the respective protein content at the end of culture (Table 1, Fig. 3).
Urea levels were similar in both groups throughout the cultivation period, being slightly higher in the 
untreated group, however without reaching statistical significance. Aspartate aminotransferase release was ini-
tially higher in the untreated group (82.37 ± 18.67 U/L vs. 52.71 ± 6.129 U/L, p = 0.009), whereas towards the 
end of culture Percoll-purified cells showed higher levels (29.98 ± 2.959 U/L vs 33.77 ± 3.622 U/L, p = 0.028). 
Albumin content decreases in both groups over the course of cell culture, however, additionally purified cells 
tended to decrease their production later and to a lesser degree than cells without Percoll purification. This 
reached statistical significance (p = 0.0004) on day 4: while Albumin content was 897.36 ng/mL (±259) without 
Percoll treatment, levels were higher on Percoll purified cells 1474.38 ng/mL (±363.2).
Parameter
High initial viability >80% Low initial viability <80%
Mean ± SEM Mean ± SEM
Number of cases 22 5
Surgical Indication
HCC 2 0
Biliary tree carcinoma 6 4
CRLM 12 0
Benign disease 2 1
Preoperative bilirubin 0.65 ± 0.08 1.21 ± 0.49
Preoperative ALT 35.32 ± 4.98 63.00 ± 19.99
Preoperative AST 41.24 ± 6.10 45.60 ± 4.41
Preoperative AP 152.50 ± 41.62 320.60 ± 108.62
Preoperative GGT 215.05 ± 59.80 356.80 ± 133.79
Preoperative INR 1.02 ± 0.01 1.04 ± 0.02
Age of donor (years) 61.50 ± 3.13 57.40 ± 7.69
Fibrosis
No Fibrosis 5 0
Minimal (periportal) 6 2
Mild (septs) 4 3
Severe Fibrosis (portocentral septs, architecture changes) 2 0
Cirrhosis (definite architectural changes) 1 0
Data not available 4 0
Steatosis
No Steatosis 2 0
≤30% Steatosis 8 0
>30% Steatosis 3 0
Data not available 9 5
Cold ischeamic time (min) 23.27 ± 3.51 15.00 ± 2.24
Time of first perfusion (min) 11.18 ± 0.56 10.50 ± 0.61
Time of second perfusion (min) 8.09 ± 0.28 8.00 ± 0.57
Mass of liver specimen (g) 16.34 ± 1.39 26.42 ± 13.42
Table 3. Subgroup features. Abbreviations: GGT, Gamma-glutamyl transpeptidase; CIT, cold ischemic time; 
AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase; INR, international 
normalized ratio; HCC, Hepatocellular carcinoma; CRLM, Colorectal liver metastasis.
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Microbiological analysis. Microbiological analysis revealed no difference in contamination rates between 
the two groups. Of the 16 isolations that underwent this investigation, 13 were sterile while three were contam-
inated. Identified pathogens were Enterococcus faecium, E. faecalis and E. coli as well as Klebsiella oxytoca and 
Staphylococcus haemolyticus. However, there was no difference between the two groups and we presume that this 
contamination most likely occurred in the operating room during retrieval of the tissue.
Cell culture purity. Purity assays showed no difference in the expression of liver-cell-specific DNA. KRT18 
levels as well as CD68 on Kupffer cells and Vimentin on fibroblasts were the same in both the crude as well as 
the Percoll-purified liver cell cultures. However, there was a slight tendency in crude, i.e. non Percoll-purified, 
preparations to express more Pecam1, which is a marker for sinusoidal endothelial cells. This reached statistical 
significance on Day 2 of culturing (2.12-fold higher expression in crude cultures, p = 0.0220). Moreover, the pres-
ence of GGT1-expressing cells, namely cholangiocytes, tends to be higher in preparations that have undergone 
Percoll purification. This trend is visible throughout the culture period, and nearly reaches statistical significance 
on day 4, when expression is 5.66-fold higher in the untreated group (p = 0.0616, Fig. 4).
Immunofluorescence staining showed no differences between the two groups and generally supports the pres-
ence of all hepatic cell types in both groups, detected by mRNA-expression profiles. While hepatocytes in the 
KRT-18-staining look compact 24 hours after seeding, they appear protruded and not as dense as at the begin-
ning of culture. This is true for both crude and Percoll-treated preparations. Interestingly, while Pecam-1-postive 
cells, i.e. endothelial cells, are also compact 24 hours after seeding, they form networks at the end of the cultur-
ing period (Fig. 5). There were again no differences detectable between the two treatment groups. Fractions of 
non-parenchymal cells were also stained, however due to difficult quantification not showed in this publication. 
Stellate cells were not found in either group. See supplementary information material for the immunofluores-
cence staining images of different non-parenchymal cell populations. Phase contrast microscopy of the cultures 
24 hours after seeding and at the end of culture revealed no differences between the two treatment groups (Fig. 6).
Subgroup analysis. When analyzing the data more thoroughly, five cases presented an initial viability 
that was lower than 80%. Percoll purification increased the viability from 71.63 (±4.44) to 87.7% (±2.69) in 
these isolations, reaching statistical significance p = 0.0299. However, no benefit in functional parameters could 
be detected. An average of 56.4% of the cells could be recovered from Percoll-purification, whereas yield was 
significantly diminished from 25.90 (±9.72) × 106 to 15.3 (±8.66) × 106 cells per gram of liver tissue (Table 2). 
When analyzing the features of this subgroup, the three cases differed from the overall group in a few known 
factors24,31–33 that are known to affect the isolation outcome, including preoperative levels of ALT, AST, AP, GGT 
and in the operating technique (Table 3).
Discussion
Isolation of primary human hepatocytes is an expensive and time-demanding process. It requires a high-level 
hepatobiliary surgical center, excellent communication between the personnel in the operation room to keep 
ischemic times as short as possible and experienced laboratory staff, as well as a well-equipped laboratory infra-
structure. Tissue specimens retrieved from the operating room for hepatocyte isolation must therefore be utilized 
as effectively as possible.
Using Percoll density centrifugation is a double-edged sword: Is the tremendous loss of cells worth the bet-
ter performance? In all publications that provide detailed information regarding the Percoll purification step 
during isolation of human liver cells22,23,33–36, the cell yield was diminished by this procedure, while the via-
bility improved. According to Schröder et al.23 who performed purification through a 50% concentrated 
Percoll-suspension, a very pure cell culture was retrieved with few contaminating non-parenchymal liver cells 
(assessed using immunohistological staining) and a viability of 94%. However, in seven of 32 experiments no cells 
were recovered after the Percoll purification step, while a low-yield after Percoll purification was reported in the 
remaining 25 trials. Olinga et al.22 declared an average recovery threshold of 33% after Percoll purification, but 
viability improved from 69% to 92%. Information on the quality and purity of the resulting cells was not reported 
though. Laba et al.34 centrifuged their cell suspensions through a 29–31%-concentrated Percoll layer before and 
after cryopreservation. Mean viability of crude cells before Percoll purification ranged up to 72% and improved 
to 89% after Percoll purification. When comparing freshly isolated crude cell suspensions to cryopreserved cells 
that were purified using the Percoll method after thawing, a positive effect on the plating efficiency was found 
after usage of Percoll (35–40% improved to 65–85%) and lower levels of non-parenchymal cells were reported. 
However, this study focused on the comparison of fresh and cryopreserved and thawed hepatocytes, while there 
was no metabolic test and the study was limited due to the low number of experiments (n = 5). These authors 
also did not directly compare cells before and after Percoll purification regarding cell culture purity and plating 
efficiency, which are determining parameters for the subsequent application of hepatocytes:
Primary human hepatocytes are widely used to study pharmacodynamic processes as well as for investigating 
processes of the hepatocyte itself. Apart from in vitro research, human hepatocytes can also be applied in the 
clinic. Since the number of donated organs for whole organ transplantation is limited, but the number of patients 
with end-stage liver diseases is rising37 the demand for an alternative to whole orthotropic liver transplantation is 
high. Hepatocytes can be used to bridge the time until a suitable donor organ is available9. Hepatocyte transplan-
tation has been successfully performed in children with inherited metabolic diseases such as Crigler-Najjar syn-
drome7,8 and in mice with hemophilia38. Primary hepatocytes can also be cultured in spheres or in multi-layered27 
cell sheet technology. These three-dimensional constructs serve as a cell-based regenerative therapy by provid-
ing metabolic function when implanted in the kidney capsules of mice. Moreover, bioengineered organs are 
under investigation to overcome the shortage of donor organs for example by using human hepatocytes to 
engraft matrices derived from decellularized livers10,39,40. Tissue engineered organs still face problems of sufficient 
9Scientific RepoRts |          (2019) 9:6542  | https://doi.org/10.1038/s41598-019-43042-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
re-endothelialization, or reperfusion injury due to inflammatory mediators secreted by Kupffer cells contaminat-
ing the hepatocyte suspension41. Therefore, providing hepatocyte cultures in high purity is necessary. In contrary 
to ours and others expectations, our data show that Percoll purification at 25% concentration significantly con-
tributes towards a more homogenously pure cell culture. Higher concentrated Percoll cushions (e.g. 50%) could 
achieve this. However, with increased silica particle density then fatty – but metabolically active – hepatocytes 
would be sorted out and lost. Hence, ideally, Percoll concentrations would be adjusted to the fat content of the 
donor’s liver. However, such an adjustment of the cell isolation procedure is not practical as often no suitable his-
topathological assessment is available prior to the isolation process. Although the overall metabolic performance 
of cells is similar in both treatment groups, AST levels differed significantly 24 hours and at the end of culture. 
We hypothesize that the difference on day 1 is due to the fact that there is more cell debris and dead cells in the 
non-Percoll-purified culture plates. This debris does not adhere for further culture, however, contributes to the 
high levels of AST in the non-purified group on day 1. The differences between albumin levels on day 4 and AST 
levels on day 6 might indicate a temporal higher metabolic activity of hepatocytes isolated with Percoll purifi-
cation which is however not consistent throughout the culture period. Our study is limited by the fact that we 
analyzed hepatocytes isolations from surgically resected liver tissue, which would most likely not be applicable for 
therapeutic use. We do, however, expect that we would obtain similar results when comparing liver cell isolations 
from whole liver grafts with vs. without Percoll purification.
Primary liver cells isolated from human tissue still face the hurdle of availability. The limited preservation 
of metabolically capable primary hepatocytes in-vitro has created an urgent need for an alternative to primary 
human hepatocytes. Even though genetically engineered hepatic cells are under thorough investigation in stem 
cell research42–45, primary human hepatocytes are still the gold standard for the applications mentioned before9,27.
Given the fact that Percoll purification could not raise the function of the cells, we suggest that density sep-
aration is only useful to sort out initial dead cells and debris – if needed. If the cell suspension has a high initial 
viability, then there is no evidence to support the need for Percoll purification. Regarding functional effects of this 
step, there are no benefits, but also no contradictions to the centrifugation through the silica-particle-layer could 
be found. If donors do not meet the criteria for ensuring a good hepatocyte isolation outcome, as reported in 
the literature, then Percoll purification could still be considered to rescue a fraction of highly viably hepatocytes.
Data Availability
The datasets generated during and analysed during the current study are available from the corresponding author 
on reasonable request.
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